JP Morgan Chase
AGIO icon

JP Morgan Chase’s Agios Pharmaceuticals AGIO Stock Holding History

JP Morgan Chase’s Portfolio AGIO Stock Details AGIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$11.4K Sell
300
-30,000
-99% -$910K ﹤0.01% 6885
2026
Q1 		$897K Hold
30,300
– – ﹤0.01% 4673
2025
Q4 		$825K Buy
30,300
+11,900
+65% +$418K ﹤0.01% 4727
2025
Q3 		$739K Hold
18,400
– – ﹤0.01% 4798
2025
Q2 		$612K Buy
+18,400
New +$558K ﹤0.01% 4669
2021
Q3 		– Sell
-30,700
Closed -$1.69M – 6450
2021
Q2 		$1.69M Hold
30,700
– – ﹤0.01% 3912
2021
Q1 		$1.58M Sell
30,700
-31,400
-51% -$1.56M ﹤0.01% 3885
2020
Q4 		$2.69M Buy
62,100
+25,700
+71% +$1.02M ﹤0.01% 3270
2020
Q3 		$1.25M Sell
36,400
-8,600
-19% -$377K ﹤0.01% 3518
2020
Q2 		$2.41M Sell
45,000
-30,000
-40% -$1.39M ﹤0.01% 2982
2020
Q1 		$2.66M Buy
75,000
+50,000
+200% +$2.31M ﹤0.01% 2755
2019
Q4 		$1.19M Hold
25,000
– – ﹤0.01% 3728
2019
Q3 		$810K Buy
+25,000
New +$1.03M ﹤0.01% 3947
2018
Q4 		– Sell
-30,000
Closed -$2.31M – 5663
2018
Q3 		$2.31M Buy
+30,000
New +$2.41M ﹤0.01% 3353

Other funds holding AGIO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM

JP Morgan Chase's AGIO Position: Q2 2026 in Review

JP Morgan Chase increased its Agios Pharmaceuticals (AGIO) stake by 137% in Q2 2026, buying an estimated $6.32M and bringing the position to 359,756 shares worth $13.8M. The position accounts for ﹤0.01% of the portfolio, ranked #2528.

JP Morgan Chase first reported a position in AGIO in Q3 2013 and has held it in 52 quarters since. The position peaked at $284M in Q2 2021. 238 funds tracked by Wall St. Rank hold AGIO as of Q2 2026.

  • JP Morgan Chase held 359,756 shares of Agios Pharmaceuticals worth $13.8M as of Q2 2026.
  • JP Morgan Chase bought 208,198 Agios Pharmaceuticals shares in Q2 2026, an estimated $6.32M.
  • Agios Pharmaceuticals made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #2528 holding.
  • JP Morgan Chase first reported a position in Agios Pharmaceuticals in Q3 2013 and has held it in 52 quarters since.
  • JP Morgan Chase's Agios Pharmaceuticals position peaked at $284M in Q2 2021.
  • 238 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.